Terms: = Sarcomas AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Clinical Outcome
12 results:
1. Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. clinical outcome and actionable molecular alterations.
Conforti F; Pala L; Pagan E; Rocco EG; Bagnardi V; Montagna E; Peruzzotti G; De Pas T; Fumagalli C; Pileggi S; Pesenti C; Marchini S; Corso G; Marchio' C; Sapino A; Graffeo R; Collet L; Aftimos P; Sotiriou C; Piccart M; Gelber RD; Viale G; Colleoni M; Goldhirsch A
Breast; 2021 Oct; 59():94-101. PubMed ID: 34217971
[TBL] [Abstract] [Full Text] [Related]
2. Survival of patients with metastatic breast cancer: a single-centre experience.
D'hondt R; Spoormans I; Neyens N; Mortier N; Van Aelst F
Acta Clin Belg; 2014 Jun; 69(3):194-9. PubMed ID: 24641516
[TBL] [Abstract] [Full Text] [Related]
3. A meta-analysis on the association of her-2 overexpression with prognosis in human osteosarcoma.
Li YG; Geng X
Eur J Cancer Care (Engl); 2010 May; 19(3):313-6. PubMed ID: 19709164
[TBL] [Abstract] [Full Text] [Related]
4. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets.
Cimbaluk D; Rotmensch J; Scudiere J; Gown A; Bitterman P
Gynecol Oncol; 2007 Apr; 105(1):138-44. PubMed ID: 17175012
[TBL] [Abstract] [Full Text] [Related]
5. Correlation of p53 and MIB-1 expression with both the systemic recurrence and survival in cases of phyllodes tumors of the breast.
Yonemori K; Hasegawa T; Shimizu C; Shibata T; Matsumoto K; Kouno T; Ando M; Katsumata N; Fujiwara Y
Pathol Res Pract; 2006; 202(10):705-12. PubMed ID: 16889904
[TBL] [Abstract] [Full Text] [Related]
6. Expression and amplification of her-2/neu oncogene in uterine carcinosarcomas: a marker for potential molecularly targeted treatment?
Raspollini MR; Susini T; Amunni G; Paglierani M; Castiglione F; Garbini F; Carriero C; Scarselli G; Taddei GL
Int J Gynecol Cancer; 2006; 16(1):416-22. PubMed ID: 16445668
[TBL] [Abstract] [Full Text] [Related]
7. COX-2, c-KIT and her-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?
Raspollini MR; Susini T; Amunni G; Paglierani M; Taddei A; Marchionni M; Scarselli G; Taddei GL
Gynecol Oncol; 2005 Jan; 96(1):159-67. PubMed ID: 15589595
[TBL] [Abstract] [Full Text] [Related]
8. Oncoproteins and proliferation markers in synovial sarcomas: a clinicopathologic study of 19 cases.
Barbashina V; Benevenia J; Aviv H; Tsai J; Patterson F; Aisner S; Cohen S; Fernandes H; Skurnick J; Hameed M
J Cancer Res Clin Oncol; 2002 Nov; 128(11):610-6. PubMed ID: 12458341
[TBL] [Abstract] [Full Text] [Related]
9. Expression of p53 gene product and cell proliferation marker Ki-67 in Ewing's sarcoma: correlation with clinical outcome.
Amir G; Issakov J; Meller I; Sucher E; Peyser A; Cohen IJ; Yaniv I; Ben Arush MW; Tavori U; Kollender Y; Ron N; Peylan-Ramu N
Hum Pathol; 2002 Feb; 33(2):170-4. PubMed ID: 11957141
[TBL] [Abstract] [Full Text] [Related]
10. Clinicopathologic analysis of her-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma.
Kilpatrick SE; Geisinger KR; King TS; Sciarrotta J; Ward WG; Gold SH; Bos GD
Mod Pathol; 2001 Dec; 14(12):1277-83. PubMed ID: 11743051
[TBL] [Abstract] [Full Text] [Related]
11. Uterine smooth muscle tumors: utility of classification by proliferation, ploidy, and prognostic markers versus traditional histopathology.
Layfield LJ; Liu K; Dodge R; Barsky SH
Arch Pathol Lab Med; 2000 Feb; 124(2):221-7. PubMed ID: 10656730
[TBL] [Abstract] [Full Text] [Related]
12. Cystosarcoma phyllodes of the breast: prognostic significance of proliferation and apoptosis associated genes.
Witte F; Hönig A; Mirecka J; Schauer A
Anticancer Res; 1999; 19(4B):3355-9. PubMed ID: 10652633
[TBL] [Abstract] [Full Text] [Related]
